🇺🇸 FDA
Patent

US 10941135

Nrf2 activating compounds and uses thereof

granted A61PA61P17/06A61P25/00

Quick answer

US patent 10941135 (Nrf2 activating compounds and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61P, A61P17/06, A61P25/00, A61P29/00, A61P37/02